Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
We’ve seen a number of approvals in multiple myeloma over the past year. Enrique M. Ocio, MD, PhD, from the University of Salamanca,
Salmanca, Spain discusses the results from recent studies presented at the European Hematology Association (EHA) 2017 meeting, as well as the novel adverse events and toxicities that these new drugs can cause.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.